A new meta-analysis study reveals that complete response rate to chemotherapy treatment remain low to common types of late-stage cancer despite of new treatment methods.
Two recent clinical studies shed light on the health challenges faced by survivors of childhood or young adult cancer.
EU regulators approved blinatumomab for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia.
U.S. regulators approved Bristol-Myers Squibb's immunotherapy drug Opdivo for the treatment of patients with advanced (metastatic) renal cell carcinoma.
US regulators approved the monoclonal antibody necitumumab Portrazza as a first-line treatment for advanced squamous non-small cell lung cancer.
Brain cancer patients survived longer when treated with Optune in combination with Avastin, a new late-stage study reveals.
U.S. regulators approved Novartis’ drug combination of Tafinlar and Mekinist for the treatment of metastatic melanoma.
Combing cobimetinib and vemurafenib extended the survival rate of previously untreated patients with advanced skin cancer, a new study reports.
European regulators approved carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma.
According to latest five year survival clinical results, patients with metastatic melanoma were benefited by IMM-101, a pancreatic cancer immunotherapy drug.
Takeda’s oral myeloma treatment, ixazomib (Ninlaro), got approved by the FDA as a second-line combination therapy.
Investigational immunotherapy increased overall survival in patients with metastatic bladder cancer, according to a new study.
U.S. regulators granted breakthrough therapy designation to avelumab for the treatment of patients with metastatic Merkel cell carcinoma.
A new study comes to explain why metastatic colorectal cancer comes back after treatment with cetuximab to some patients.
Taking intensive yoga classes helped patients undergoing prostate cancer treatment improve their general well-being, a new research shows.
The FDA approved Johnson & Johnson’s immunotherapy drug, Darzalex (daratumumab) for the treatment of patients with advanced multiple myeloma.
A new study reveals the relationship between psychological factors and nausea and vomiting during chemotherapy of cancer.
U.S. regulators approved osimertinib for the treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
Patients with mantle cell lymphoma benefited from the drug combination of rituximab plus lenalidomide, a new study shows.
Ovarian cancer patients who had previously taken birth control pills had improved progression-free survival according to a new study.
The U.S FDA approved Cotellic for the treatment of patients with untreated BRAF V600 mutation-positive advanced melanoma.
A new study revealed the effectiveness and the safety profile of surgical lung resection for high-risk patients with early stage lung cancer.
A patient with a BRAF-mutant brain tumor benefited from the melanoma treatment, dabrafenib, revealing the potential of the drug against this type of brain tumor.
An investigational immunotherapy appears effective in treating patients with metastatic urothelial cancer, two recent trials report.
Neuroscientists report that permanent hearing loss resulting from chemotherapy may contribute to long-term neurocognitive deficits in pediatric brain tumor survivors.
A short course of oral vemurafenib was found to be highly effective in patients with relapsed/refractory hairy cell leukemia, two separate, phase 2 studies reveal.
Treating liver cancer patients with higher doses of radiotherapy increased long-term survival rates that compare favorably with resection, a study showed.
Olaparib, a drug against inherited cancer mutations, was found to benefit as many as a third of patients with prostate cancer, a new study reveals.
Women at high-risk of breast cancer could benefit from regular physical activity, according to a new research.
Patients of renal cell carcinoma benefited significantly when treated with a combination of lenvatinib with everolimus, a new phase 2 study reveals.